A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...

WASHINGTON, DC — A fast-acting transdermal gel using a proprietary formulation of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen (Topofen, Achelios Therapeutics) reduced pain severity in ...

Nobelpharma America has become the first company to win FDA approval for a topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC). The approval covers a topical gel ...

When I strained a back muscle playing tennis not long ago, my doubles partner, who happened to be a doctor, pulled a tube of cream from her gym bag and told me to rub it on. It wasn’t Bengay or one of ...

Researchers have developed a new gel formulation for the treatment of erectile dysfunction. This gel formulation contains nitrates or nitroglycerine that is being used to treat angina chest pain and ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

Credit: Chiesi Global Rare Diseases. Filsuvez is a sterile botanical drug product that contains a dry extract from 2 species of birch bark. Findings showed 41.3% of patients treated with Filsuvez had ...

See more of our coverage in your search results. It’s helping couples gel — literally. A first-of-its-kind topical gel to treat erectile dysfunction has been given the OK from the Food and Drug ...

A group of researchers in India has developed a topical skin gel they hope farmers and landscape workers can use to minimize the neurotoxic effects of organophosphate pesticides (Sci. Adv.2018, DOI: ...

An innovative gel treatment has shown early promise for treating the most common type of skin cancer. The new results from a clinical trial were published in the journal Clinical Cancer Research and ...

Please provide your email address to receive an email when new articles are posted on . Phase 2a interim data show 100% of patients achieving the primary endpoint of skin toxicity improvement. Also, ...